With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.

Digital systems, automation, and flexibility are crucial for overcoming the hurdles associated with the development and manufacture of next-gen therapies, but ongoing investment is critical to ensure continued innovation in the sector.

Affordability and accessibility are critical factors for commercial success of next-gen therapies; however, greater industry collaboration is needed to reduce inefficiencies in the development of advanced technologies.

In this interview, David Phasey from 3P innovation highlights why advanced technologies are critical to helping companies overcome the challenges associated with the development and manufacture of next-generation therapies.

Despite the numerous challenges facing the development, manufacture, and commercialization of next-generation therapies, the end value proposition they offer is significant and worth the effort from stakeholders.

With digitalization gaining traction in biomanufacturing, The Pharma Navigator speaks to experts about how digital twins and advanced modeling are helping companies meet industry demands and what that means for the workforce.

While meaningful progress has been made by the biopharmaceutical industry into digitalization, there is still a lot of work to do to achieve a true digital transformation.

Strategic early planning, optimal CDMO selection, careful scale management, and stringent quality, along with greater industry collaboration, will ensure future biomanufacturing success.

As the complexity of drug molecules evolve and patient expectations grow, industry leaders reveal why the next generation of drug delivery must balance cutting-edge science, flexible manufacturing, and patient-centric design.

With a grant of £1 million from Innovate UK, Cellular Origins, the CGT Catapult, and Resolution Therapeutics will work together to create a fully automated, scalable cell therapy manufacturing platform.

Cell therapies are distinct from other therapies, meaning that CDMOs shouldn’t take a cookie-cutter approach to these unique projects, notes Nirupama Pike from Catalent in this post-BIO 2025 interview.

The new system has been designed to deliver vaccines and other drug products intradermally, which offers advantages over other forms of injectable administration.

The biologics sector is rapidly evolving thanks to scientific innovation and investment. In this article, insights and perspectives from a selection of senior leaders shaping the future of biologics are reviewed.

Epigenetic modulation has been important in the development of oncology therapies, but its use in cardiovascular diseases is just beginning. In this pre-BIO interview, Sten Sörensen from Cereno Scientific provides some insights into developments in this field.

Prior to BIO 2025, Russell Miller from Enzene Biosciences highlights how a fully connected continuous manufacturing platform is enhancing biologics production and, hence, improving patient access.

Solid tumors are difficult to treat as a result of numerous factors, in this interview, Oury Chetboun from Seekyo Therapeutics, details how targeting functional proteins in the tumor microenvironment can help.

Treating metastases with an external laser beam can prove challenging; however, radiotherapeutics are providing more targeted treatment options, radiating the tumor cells from within, specifies David Bejker from Affibody.